A Disproportionality Analysis of Drug–Drug Interactions of Tizanidine and CYP1A2 Inhibitors from the FDA Adverse Event Reporting System (FAERS)-Reference-Cited by-同舟云学术

A Disproportionality Analysis of Drug–Drug Interactions of Tizanidine and CYP1A2 Inhibitors from the FDA Adverse Event Reporting System (FAERS)

Published:2022-07-14 Issue:8 Volume:45 Page:863-871
ISSN:0114-5916
Container-title:Drug Safety
language:en
Short-container-title:Drug Saf

Author:

Villa-Zapata Lorenzo^ORCID,Gómez-Lumbreras Ainhoa^ORCID,Horn John^ORCID,Tan Malinda S.,Boyce Richard D.^ORCID,Malone Daniel C.^ORCID

Funder

Agency for Healthcare Research and Quality

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Toxicology

Link

https://link.springer.com/content/pdf/10.1007/s40264-022-01200-4.pdf

Reference47 articles.

1. Giovannitti JA, Thoms SM, Crawford JJ. Alpha-2 adrenergic receptor agonists: a review of current clinical applications. Anesth Prog. 2015;62:31–8.

2. Peck J, Urits I, Crane J, McNally A, Noor N, Patel M, et al. Oral muscle relaxants for the treatment of chronic pain associated with cerebral palsy. Psychopharmacol Bull. 2020;50(4 Suppl 1):142–62.

3. Paisley S, Beard S, Hunn A, et al. Clinical effectiveness of oral treatments for spasticity in multiple sclerosis: a systematic review. Mult Scler. 2002;8:319–29.

4. Malanga G, Reiter RD, Garay E. Update on tizanidine for muscle spasticity and emerging indications. Expert Opin Pharmacother. 2008;9:2209–15.

5. Semenchuk MR, Sherman S. Effectiveness of tizanidine in neuropathic pain: an open-label study. J Pain. 2000;1:285–92.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovering clinical drug-drug interactions with known pharmacokinetics mechanisms using spontaneous reporting systems and electronic health records;Journal of Biomedical Informatics;2024-05

2. Exploring the impact of co-exposure timing on drug-drug interactions in signal detection through spontaneous reporting system databases: a scoping review;Expert Review of Clinical Pharmacology;2024-04-18

3. Authors’ Response to Yoshihiro Noguchi’s Comment on: “A Disproportionality Analysis of Drug-Drug Interactions of Tizanidine and CYP1A2 Inhibitors from the FDA Adverse Event Reporting System (FAERS)”;Drug Safety;2022-10-12

4. Comment on: "A Disproportionality Analysis of Drug–Drug Interactions of Tizanidine and CYP1A2 Inhibitors from the FDA Adverse Event Reporting System (FAERS)";Drug Safety;2022-10-12

5. Drug interaction safety signals for tizanidine identified;Reactions Weekly;2022-07